Year All2026202520242023 June 2, 2026 Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics May 8, 2026 Alamar Biosciences Reports First Quarter 2026 Financial Results May 5, 2026 Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference April 30, 2026 Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026 April 20, 2026 Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares April 16, 2026 Alamar Biosciences Announces Pricing of Upsized Initial Public Offering March 17, 2026 Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research January 12, 2026 Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research January 11, 2026 Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
June 2, 2026 Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
April 20, 2026 Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 17, 2026 Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research
January 12, 2026 Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research
January 11, 2026 Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
